Mathieu Gonçalves-Venturelli
Research Subjects
Mathieu Gonçalves-Venturelli has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Charles-Frédéric Mantion
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
26 shared publications - Evan Seffar
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
26 shared publications - Francine Garnache-Ottou
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
26 shared publications - Maxime Fredon
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
26 shared publications - Olivier Adotévi
Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, Besançon 25000, France; Department of Medical Oncology, University Hospital of Besançon, Besançon 25000, France
26 shared publications - Yann Godet
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
26 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Supplementary Table S1. Homology of SALL4-derived S9V peptide sequence in human proteome
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Supplementary Table S1. Homology of SALL4-derived S9V peptide sequence in human proteome
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Immunophenotyping profile of SALL4-TCR T cells. (A) Memory phenotype: TN/TSCM (CD45RA+, CD62L+), TEMRA (CD62L-, CD45RA+), TCM (CD62L+, CD45RA-) and TEM (CD45RA-, CD62L-) subset distribution in unstimulated and S9V stimulated primary T cells redirected to express SALL4-TCR (n=4). (B) t-SNE representation of the expression of extracellular activation markers and immune checkpoint molecules (CD69, HLA-DR, 4-1BB, PD1, LAG3, and TIM3) of unstimulated and stimulated SALL4-TCR T cells. (C) Expression of CD69, HLA-DR, 4-1BB, PD1, LAG3, and TIM3 on unstimulated and stimulated SALL4-TCR T cells. (D) Co-expression of pairs of checkpoint markers (PD1, TIM3, LAG3, and TIGIT). (E) Expression of chemokine receptors CXCR2, CXCR3, CXCR4, CXCR6, CX3CR1 and CCR4 on SALL4-TCR T cells. (F) Quantification of released analytes including TNF-α, IFNγ, granzyme A, granzyme B, IL2, IL4, and perforin assessed by Legendplex analysis in cell culture supernatants of SALL4-TCR T cells previously stimulated or not during 5h with S9V peptide at different concentration [0-10µg/mL] (n = 4).
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Immunophenotyping profile of SALL4-TCR T cells. (A) Memory phenotype: TN/TSCM (CD45RA+, CD62L+), TEMRA (CD62L-, CD45RA+), TCM (CD62L+, CD45RA-) and TEM (CD45RA-, CD62L-) subset distribution in unstimulated and S9V stimulated primary T cells redirected to express SALL4-TCR (n=4). (B) t-SNE representation of the expression of extracellular activation markers and immune checkpoint molecules (CD69, HLA-DR, 4-1BB, PD1, LAG3, and TIM3) of unstimulated and stimulated SALL4-TCR T cells. (C) Expression of CD69, HLA-DR, 4-1BB, PD1, LAG3, and TIM3 on unstimulated and stimulated SALL4-TCR T cells. (D) Co-expression of pairs of checkpoint markers (PD1, TIM3, LAG3, and TIGIT). (E) Expression of chemokine receptors CXCR2, CXCR3, CXCR4, CXCR6, CX3CR1 and CCR4 on SALL4-TCR T cells. (F) Quantification of released analytes including TNF-α, IFNγ, granzyme A, granzyme B, IL2, IL4, and perforin assessed by Legendplex analysis in cell culture supernatants of SALL4-TCR T cells previously stimulated or not during 5h with S9V peptide at different concentration [0-10µg/mL] (n = 4).
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR T cells recognize natural SALL4+ cancer cell lines in an HLA-A2 restricted manner.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR T cells recognize natural SALL4+ cancer cell lines in an HLA-A2 restricted manner.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Expression of SALL4-TCR in Jurkat TCR KO CD8+ T cells via mRNA electroporation. Representative FACS SALL4-teramer staining on Jurkat TCR KO CD8+ T cells electroporated with mRNA encoding α and β subunits for the SALL4-TCR (right) or an irrelevant-TCR (middle). Mock electroporated cells (no mRNA, left) were used for negative control.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Expression of SALL4-TCR in Jurkat TCR KO CD8+ T cells via mRNA electroporation. Representative FACS SALL4-teramer staining on Jurkat TCR KO CD8+ T cells electroporated with mRNA encoding α and β subunits for the SALL4-TCR (right) or an irrelevant-TCR (middle). Mock electroporated cells (no mRNA, left) were used for negative control.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Supplementary Table S2: List of antibodies and flow cytometry regents used
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Supplementary Table S2: List of antibodies and flow cytometry regents used
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR T cells exhibit anti-tumor activity in vivo.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
SALL4-TCR T cells exhibit anti-tumor activity in vivo.